RESEARCH TRIANGLE, N.C.--(

研究三角，N.C--(

BUSINESS WIRE

商业热线

)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it has entered a new funded collaboration with the Enabling Technologies Consortium (ETC).

)--Simulations Plus，Inc.（纳斯达克股票代码：SLP）（“Simulations Plus”）是生物模拟、模拟性能和智能解决方案以及生物制药行业医疗通信的领先供应商，今天宣布，它已与enabled Technologies Consortium（ETC）进行了新的资金合作。

This partnership is aimed at advancing .

这种伙伴关系旨在推进。

in vitro-in vivo

体外-体内

correlation (IVIVC) approaches for oral drug delivery and expanding the functionality of the GastroPlus platform.

用于口服药物递送和扩展GastroPlus平台功能的相关性（IVIVC）方法。

The collaboration focuses on enhancing the predictive capabilities of the GastroPlus advanced compartmental absorption and transit (ACAT™) model to support the development of immediate release (IR) oral drug products. Using data gathered from public sources and members of the ETC, physiologically based pharmacokinetics (PBPK) and biopharmaceutics modeling (PBBM) experts and software engineers at Simulations Plus will look to complete key objectives as defined by the partnership.

该合作的重点是增强GastroPlus高级隔室吸收和转运（ACAT™）模型的预测能力，以支持立即释放（IR）口服药物产品的开发。Simulations Plus的生理药代动力学（PBPK）和生物制药建模（PBBM）专家和软件工程师将利用从公共来源和ETC成员收集的数据，完成合作伙伴关系定义的关键目标。

These advancements, including implementation of novel product-particle size distribution (P-PSD) methodologies and enhanced food effect modeling features, will provide researchers with powerful tools to improve drug product development, reduce reliance on animal studies, and streamline regulatory submissions..

这些进步，包括实施新的产品粒度分布（P-PSD）方法和增强的食品效应建模功能，将为研究人员提供强大的工具，以改进药品开发，减少对动物研究的依赖，并简化监管提交。。

“We are honored to collaborate with ETC, a consortium representing leaders in pharmaceutical innovation who recognize the critical role GastroPlus already plays in drug development,” said Dr. Xavier Pepin, Vice President of PBPK R&D at Simulations Plus and principal investigator for this project. “This partnership reflects the trust and confidence the industry places in our platform and the desire to support its continued evolution.

Simulations Plus PBPK研发副总裁兼该项目首席研究员Xavier Pepin博士表示：“我们很荣幸与ETC合作，ETC是一个代表制药创新领导者的财团，他们认识到GastroPlus在药物开发中已经发挥的关键作用。”。“这种合作关系反映了业界对我们平台的信任和信心，以及支持其持续发展的愿望。

By advancing cutting-edge capabilities, we are not only reaffirming our commitment to innovation but also empowering researchers to solve complex biopharmaceutical challenges with even greater precision and efficiency.”.

通过提高尖端能力，我们不仅重申了我们对创新的承诺，而且赋予研究人员更高的精确度和效率来解决复杂的生物制药挑战。”。

The collaboration leverages the combined expertise of Simulations Plus and ETC’s Participating Members, which include leading pharmaceutical and biotechnology companies. Throughout the project, Simulations Plus will deliver beta versions of the enhanced GastroPlus platform to ETC members for testing.

该合作利用了Simulations Plus和ETC参与成员的综合专业知识，其中包括领先的制药和生物技术公司。在整个项目中，Simulations Plus将向ETC成员提供增强GastroPlus平台的测试版以进行测试。

Upon completion, the updated software will be accessible to the broader user community. Consistent with all collaborations that Simulations Plus enters, the Company will retain ownership of intellectual property developed through this partnership, ensuring that future enhancements to its platform continue to reflect Simulations Plus’ leadership in PBPK/PBBM science..

完成后，更广泛的用户社区将可以访问更新后的软件。与Simulations Plus参与的所有合作一致，该公司将保留通过该合作关系开发的知识产权的所有权，确保其平台的未来增强继续反映Simulations Plus在PBPK/PBBM科学领域的领先地位。。

About the Enabling Technologies Consortium

关于赋能技术联盟

The Enabling Technologies Consortium (ETC) serves as a dynamic platform for pharmaceutical and biotechnology companies to exchange ideas, share knowledge, and collaborate on pioneering new technologies that enhance drug development and manufacturing processes. With a mission centered on advancing pre-competitive enabling technologies, ETC fosters partnerships between its member companies and external collaborators.

赋能技术联盟（ETC）为制药和生物技术公司提供了一个动态平台，可以交流想法，分享知识，并就促进药物开发和制造过程的开创性新技术进行合作。ETC的使命是推进竞争前的使能技术，促进其成员公司与外部合作者之间的伙伴关系。

Pre-competitive initiatives are defined as joint efforts among multiple pharmaceutical organizations and third parties to develop tools, methodologies, or refinements that drive efficiencies in drug development. These outcomes are made widely accessible through publication, product commercialization, or other dissemination methods..

竞争前举措被定义为多个制药组织和第三方共同努力开发工具，方法或改进，以提高药物开发的效率。通过出版、产品商业化或其他传播方法，可以广泛获取这些成果。。

By uniting industry leaders under a shared vision, ETC is driving progress and empowering pharmaceutical companies to tackle common challenges with innovative, enabling technologies. For more information about ETC and its initiatives, please visit

通过在共同愿景下团结行业领导者，ETC正在推动进步，并赋予制药公司以创新的、有利的技术应对共同挑战的能力。有关ETC及其举措的更多信息，请访问

https://www.etconsortium.org/

https://www.etconsortium.org/

.

.

About Simulations Plus, Inc.

关于Simulations Plus，Inc。

With more than 25 years of experience serving clients globally, Simulations Plus stands as a premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization.

Simulations Plus拥有超过25年的全球客户服务经验，是生物制药领域的领先供应商，提供先进的软件和咨询服务，可增强药物发现、开发、研究、临床试验操作、监管提交和商业化。

Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development.

我们全面的生物模拟解决方案集成了人工智能/机器学习（AI/ML），基于生理的药代动力学，基于生理的生物制药，定量系统药理学/毒理学和群体PK/PD建模方法。我们还提供支持模拟的性能和智能解决方案，以及用于临床和商业药物开发的医疗通信支持。

Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at .

我们的尖端技术已获得全球领先的制药、生物技术和监管机构的许可和使用。有关更多信息，请访问我们的网站：。

www.simulations-plus.com

www.simulations-plus.com

. Follow us on

.继续关注我们

LinkedIn

LinkedIn

|

|

X

十

|

|

YouTube

YouTube

.

.

Environmental, Social, and Governance (ESG)

环境、社会和治理（ESG）

We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our

我们将环境、社会和治理（ESG）的工作重点放在能够产生最积极影响的地方。要了解更多有关我们最新举措和优先事项的信息，请访问我们的网站阅读我们的

2023 ESG update.

2023年ESG更新。

Forward-Looking Statements

前瞻性声明

Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like “believe,” “expect,” and “anticipate” mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements.

除历史信息外，本新闻稿中讨论的事项是涉及风险和不确定性的前瞻性声明。像“相信”、“期望”和“期望”这样的词意味着这些是我们在撰写本文时的最佳估计，但不能保证预期或预期的结果或事件会实际发生，因此我们未来的实际结果可能与这些陈述有很大差异。

Factors that could cause or contribute to such differences include, but are not limited to: our ability to successfully integrate the Pro-ficiency business with our own, as well as expenses we may incur in connection therewith, the efficiency and effectiveness of our internal business restructuring and leadership changes, our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market.

可能导致或促成这种差异的因素包括但不限于：我们成功将高效业务与我们自己的业务整合的能力，以及我们可能产生的相关费用，我们内部业务重组和领导层变化的效率和有效性，我们保持竞争优势的能力，客户接受新软件和现有软件的改进版本，制药行业的一般经济，我们为增长融资的能力，我们继续吸引和留住高素质技术人员的能力，市场条件，宏观经济因素以及可持续的市场。

Further information on our risk factors is contained in our quarterly and annual reports and filed with the U.S. Securities and Exchange Commission..

有关我们风险因素的更多信息，请参阅我们的季度和年度报告，并提交给美国证券交易委员会。。